Cargando…

Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer

Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell’s death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse can...

Descripción completa

Detalles Bibliográficos
Autores principales: Szijj, Peter A., Gray, Melissa A., Ribi, Mikaela K., Bahou, Calise, Nogueira, João C. F., Bertozzi, Carolyn R., Chudasama, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624612/
https://www.ncbi.nlm.nih.gov/pubmed/37488375
http://dx.doi.org/10.1038/s41557-023-01280-4
_version_ 1785130952146550784
author Szijj, Peter A.
Gray, Melissa A.
Ribi, Mikaela K.
Bahou, Calise
Nogueira, João C. F.
Bertozzi, Carolyn R.
Chudasama, Vijay
author_facet Szijj, Peter A.
Gray, Melissa A.
Ribi, Mikaela K.
Bahou, Calise
Nogueira, João C. F.
Bertozzi, Carolyn R.
Chudasama, Vijay
author_sort Szijj, Peter A.
collection PubMed
description Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell’s death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse cancer-cell immune-dampening strategies, improving efficacy. So far, protein engineering has been the main approach to generate bsAbs and CiTEs, but improved chemical methods for their generation have recently been developed. Homogeneous fragment-based bsAbs constructed from fragment antigen-binding regions (Fabs) can be generated using click chemistry. Here we describe a chemical method to generate biotin-functionalized three-protein conjugates, which include two CiTE molecules, one containing an anti-PD-1 Fab and the other containing an immunomodulatory enzyme, Salmonella typhimurium sialidase. The CiTEs’ efficacy was shown to be superior to that of the simpler BiTE scaffold, with the sialidase-containing CiTE inducing substantially enhanced T cell-mediated cytotoxicity in vitro. The chemical method described here, more generally, enables the generation of multi-protein constructs with further biological applications. [Image: see text]
format Online
Article
Text
id pubmed-10624612
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106246122023-11-05 Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer Szijj, Peter A. Gray, Melissa A. Ribi, Mikaela K. Bahou, Calise Nogueira, João C. F. Bertozzi, Carolyn R. Chudasama, Vijay Nat Chem Article Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell’s death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse cancer-cell immune-dampening strategies, improving efficacy. So far, protein engineering has been the main approach to generate bsAbs and CiTEs, but improved chemical methods for their generation have recently been developed. Homogeneous fragment-based bsAbs constructed from fragment antigen-binding regions (Fabs) can be generated using click chemistry. Here we describe a chemical method to generate biotin-functionalized three-protein conjugates, which include two CiTE molecules, one containing an anti-PD-1 Fab and the other containing an immunomodulatory enzyme, Salmonella typhimurium sialidase. The CiTEs’ efficacy was shown to be superior to that of the simpler BiTE scaffold, with the sialidase-containing CiTE inducing substantially enhanced T cell-mediated cytotoxicity in vitro. The chemical method described here, more generally, enables the generation of multi-protein constructs with further biological applications. [Image: see text] Nature Publishing Group UK 2023-07-24 2023 /pmc/articles/PMC10624612/ /pubmed/37488375 http://dx.doi.org/10.1038/s41557-023-01280-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Szijj, Peter A.
Gray, Melissa A.
Ribi, Mikaela K.
Bahou, Calise
Nogueira, João C. F.
Bertozzi, Carolyn R.
Chudasama, Vijay
Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
title Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
title_full Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
title_fullStr Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
title_full_unstemmed Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
title_short Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
title_sort chemical generation of checkpoint inhibitory t cell engagers for the treatment of cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624612/
https://www.ncbi.nlm.nih.gov/pubmed/37488375
http://dx.doi.org/10.1038/s41557-023-01280-4
work_keys_str_mv AT szijjpetera chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer
AT graymelissaa chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer
AT ribimikaelak chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer
AT bahoucalise chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer
AT nogueirajoaocf chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer
AT bertozzicarolynr chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer
AT chudasamavijay chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer